Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals, Inc. CFO, EVP & Treasurer William J. Peters sold 4,139 shares of Common Stock at $25 per share on September 21, 2026, leaving him with 168,707 shares held directly. The reported balance is his direct position after the transaction, not the number of shares sold. The sale was made under a Rule 10b5-1 trading plan adopted on March 10, 2026.
Amphastar Pharmaceuticals, Inc. (AMPH) has a notice of proposed resale of common stock under Rule 144 filed on behalf of officer William J. Peters. The notice covers 4,139 shares of common stock held at UBS Financial Services Inc., with an indicated aggregate value of $103,475.00 and a proposed sale date of September 21, 2026 on NASDAQ. The shares to be sold were acquired through RSU vesting on March 17, 2024, and the notice also reports a prior sale of 8,180 shares for $183,886.40 on August 7, 2026.
Amphastar Pharmaceuticals, Inc. (AMPH) officer Rong Zhou, Senior EVP, Production Center, exercised options for 10,000 shares of common stock on September 16, 2026 at an exercise price of $13.35 per share and sold 10,000 shares the same day at a weighted average price of $23.94. Following the option exercise, Zhou held 19,424 stock options directly, and also has indirect ownership interests in common shares held by the Zhou Family Trust and by the reporting person’s spouse.
Amphastar Pharmaceuticals, Inc. (AMPH) executive Rong Zhou, Senior EVP, Production Center, reported selling 3,187 shares of common stock on September 2, 2026 in an open-market or private transaction at a weighted average price of $23.6291 per share, with trade prices ranging from $23.62 to $23.69.
After this sale, Zhou directly holds 169,203 shares of Amphastar common stock, including 836 shares acquired on May 31, 2026 under the company’s 2014 Employee Stock Purchase Plan. Additional indirect holdings are reported through the Zhou Family Trust and the reporting person’s spouse. No Rule 10b5-1 trading plan is reported.
Amphastar Pharmaceuticals, Inc. (AMPH) is the issuer for a planned resale of its common stock under Rule 144 by Rong Zhou, identified as Vice President. The notice covers several blocks of common stock, including 10,000 shares acquired via an option exercise dated 09/01/2026 and additional smaller lots acquired through the company’s Employee Stock Purchase Plan on various dates from 2021 to 2023.
Amphastar Pharmaceuticals, Inc. (symbol AMPH) has a notice of proposed sale under Rule 144 for its common stock. Floyd Petersen plans to sell 47,101 shares of Amphastar common stock through UBS Financial Services Inc., with an indicated aggregate market value of 989,121. Amphastar reports that 44,092,000 shares of this class of common stock are outstanding. The shares to be sold were acquired from the issuer via an option exercise for cash, with the form listing 08/18/2026 as both the acquisition and proposed sale date, and identifying NASDAQ as the exchange.
Amphastar Pharmaceuticals, Inc. director Richard K. Prins reported a sale of 7,973 shares of common stock on 2026-08-11 in a sale in open market or private transaction at $20.30 per share. Following this transaction, he directly holds 29,625 shares of Amphastar common stock.
Amphastar Pharmaceuticals, Inc. director and CFO/EVP/Treasurer William J. Peters reported an options exercise and share sale. On August 7, 2026, he exercised 5,053 Employee Stock Options at an exercise price of $19.79 per share, receiving 5,053 shares of common stock and closing out that option grant. The same day, he sold 8,180 shares of common stock at $22.48 per share in a transaction described as a sale in the open market or a private transaction. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. A related holding footnote states that reported common stock holdings include 910 shares acquired on May 31, 2026 under the company’s 2014 Employee Stock Purchase Plan.
AMPH filed a notice of a proposed sale of common stock under Rule 144. The filing lists UBS Financial Services Inc as broker for a transaction involving 7,973 shares of common stock with an aggregate market value of $161,931.63, referencing 44,009,000 shares outstanding and a proposed sale date of 08/11/2026 on NASDAQ. The shares derive from multiple RSU vesting events between 2017 and 2025, including grants that vested in 2017, 2018, 2019, 2020, 2024, and 2025.